Vaccine against norovirus

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 6, 2014, Pages 1449-1456

  Tan, Ming ^a,b   Jiang, Xi ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Calicivirus; Norovirus; P particle; Vaccine platform; VLP vaccine

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

CALICIVIRIDAE INFECTIONS; CLASSIFICATION; DRUG DEVELOPMENT; GASTROENTERITIS; GENETIC VARIABILITY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; NOROVIRUS; PHASE 2 CLINICAL TRIAL (TOPIC); TRENDS;

CALICIVIRIDAE INFECTIONS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DISCOVERY; GASTROENTERITIS; GENETIC VARIATION; HUMANS; NOROVIRUS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84905826243     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28626     Document Type: Review

References (102)

1. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastañaduy PA, Vinjé J, Parashar UD. Norovirus disease in the United States. Emerg Infect Dis 2013; 19:1198-205; PMID:23876403; http://dx.doi.org/10.3201/eid1908.130465
2. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinjé J, Parashar UD. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg Infect Dis 2008; 14:1224-31; PMID:18680645; http://dx.doi.org/10.3201/eid1408.071114
3. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002; 185:1335-7; PMID:12001052; http://dx.doi.org/10.1086/339883
4. Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. Human susceptibility and resistance to Norwalk virus infection. Nat Med 2003; 9:548-53; PMID:12692541; http://dx.doi.org/10.1038/ nm860
5. Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, Dickey M, McNeal M, Jiang X. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386-93; PMID:22927452; http://dx.doi.org/10.1093/infdis/jis514
6. Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis 2010; 202:1212-8; PMID:20815703; http://dx.doi.org/10.1086/656364
7. Jiang X, Matson DO, Ruiz-Palacios GM, Hu J, Treanor J, Pickering LK. Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein. J Clin Microbiol 1995; 33:1452-5; PMID:7650166
8. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992; 66:6527-32; PMID:1328679
9. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science 1999; 286:287-90; PMID:10514371; http://dx.doi.org/10.1126/science.286.5438.287
10. Jiang X, Zhong WM, Farkas T, Huang PW, Wilton N, Barrett E, Fulton D, Morrow R, Matson DO. Baculovirus expression and antigenic characterization of the capsid proteins of three Norwalk-like viruses. Arch Virol 2002; 147:119-30; PMID:11855626; http://dx.doi.org/10.1007/s705-002-8306-5
11. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010; 9:299-307; PMID:20218858; http://dx.doi.org/10.1586/erv.09.163
12. Huang P, Farkas T, Marionneau S, Zhong W, Ruvoën-Clouet N, Morrow AL, Altaye M, Pickering LK, Newburg DS, LePendu J, et al. Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis 2003; 188:19-31; PMID:12825167; http://dx.doi.org/10.1086/375742
13. Huang P, Farkas T, Zhong W, Tan M, Thornton S, Morrow AL, Jiang X. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol 2005; 79:6714-22; PMID:15890909; http://dx.doi.org/10.1128/JVI.79.11.6714-6722.2005
14. Tan M, Jiang X. Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle. Trends Microbiol 2005; 13:285-93; PMID:15936661; http://dx.doi.org/10.1016/j.tim.2005.04.004
15. Tan M, Jiang X. Norovirus-host interaction: implications for disease control and prevention. Expert Rev Mol Med 2007; 9:1-22; PMID:17623487; http://dx.doi.org/10.1017/S1462399407000348
16. Tan M, Jiang X. Norovirus gastroenteritis, carbohydrate receptors, and animal models. PLoS Pathog 2010; 6:e1000983; PMID:20865168; http://dx.doi.org/ 10.1371/journal.ppat.1000983
17. Tan M, Jiang X. 2010. Virus-Host Interaction and Celluar Receptors of Caliciviruses, p. 111-130. In Hansman G, Jiang X, Green K (ed.), Caliciruses. Caister Academic Press, Norwich.
18. Plummer EM, Manchester M. Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010; In press; PMID:20872839.
19. Zhao Q, Li S, Yu H, Xia N, Modis Y. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol 2013; 31:654-63; PMID:24125746; http://dx.doi.org/10.1016/j. tibtech.2013.09.002
20. Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol 2002; 76:730-42; PMID:11752163; http://dx.doi.org/10.1128/JVI.76.2.730-742.2002
21. Ma Y, Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol 2011; 85:2942-52; PMID:21228240; http://dx.doi.org/10.1128/JVI.02332-10
22. Taube S, Kurth A, Schreier E. Generation of recombinant norovirus-like particles (VLP) in the human endothelial kidney cell line 293T. Arch Virol 2005; 150:1425-31; PMID:15789263; http://dx.doi.org/10.1007/s00705-005-0517-x
23. Xia M, Farkas T, Jiang X. Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 2007; 79:74-83; PMID:17133551; http://dx.doi.org/10.1002/jmv.20762
24. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996; 93:5335-40; PMID:8643575; http://dx.doi.org/10.1073/pnas.93.11.5335
25. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000; 182:302-5; PMID:10882612; http://dx.doi.org/10. 1086/315653
26. Souza AC, Vasques RM, Inoue-Nagata AK, Lacorte C, Maldaner FR, Noronha EF, Nagata T. Expression and assembly of Norwalk virus-like particles in plants using a viral RNA silencing suppressor gene. Appl Microbiol Biotechnol 2013; 97:9021-7; PMID:23925532; http://dx.doi.org/10.1007/s00253-013-5077-5
27. Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol J 2006; 4:419-32; PMID:17177807; http://dx.doi.org/ 10.1111/j.1467-7652.2006.00191.x
28. Santi L, Huang Z, Mason H. 2006. Virus-like particles production in green plants. Methods (San Diego, Calif 40:66-76.
29. Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine 2008; 26:1846-54; PMID:18325641; http://dx.doi.org/10.1016/j.vaccine.2008.01.053
30. Kissmann J, Ausar SF, Foubert TR, Brock J, Switzer MH, Detzi EJ, Vedvick TS, Middaugh CR. Physical stabilization of Norwalk virus-like particles. J Pharm Sci 2008; 97:4208-18; PMID:18300304; http://dx.doi.org/10.1002/jps.21315
31. Koho T, Mäntylä T, Laurinmäki P, Huhti L, Butcher SJ, Vesikari T, Kulomaa MS, Hytönen VP. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J Virol Methods 2012; 181:6-11; PMID:22265819; http://dx.doi.org/10.1016/j.jviromet.2012.01.003
32. Koho T, Huhti L, Blazevic V, Nurminen K, Butcher SJ, Laurinmäki P, Kalkkinen N, Rönnholm G, Vesikari T, Hytönen VP, et al. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods 2012; 179:1-7; PMID:21600929; http://dx.doi.org/10. 1016/j.jviromet.2011.05.009
33. Herbst-Kralovetz M, Mason HS, Chen Q. Norwalk virus-like particles as vaccines. Expert Rev Vaccines 2010; 9:299-307; PMID:20218858; http://dx.doi.org/10.1586/erv.09.163
34. Willyard C. First vaccines targeting 'cruise ship virus' sail into clinical trials. Nat Med 2013; 19:1076-7; PMID:24013733; http://dx.doi.org/10. 1038/nm0913-1076
35. Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998; 72:1345-53; PMID:9445035
36. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 2001; 75:9713-22; PMID:11559804; http://dx.doi.org/10.1128/JVI.75.20.9713-9722.2001
37. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010; 17:1850-8; PMID:20962211; http://dx.doi.org/10.1128/CVI.00230-10
38. LoBue AD, Lindesmith L, Yount B, Harrington PR, Thompson JM, Johnston RE, Moe CL, Baric RS. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine 2006; 24:5220-34; PMID:16650512; http://dx.doi.org/10.1016/j.vaccine.2006.03.080
39. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol 2009; 83:3212-27; PMID:19176631; http://dx.doi.org/10.1128/JVI.01650-08
40. Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine 2012; 30:3580-6; PMID:22469864; http://dx.doi.org/10.1016/j.vaccine.2012.03.050
41. Richardson C, Bargatze RF, Goodwin R, Mendelman PM. Norovirus virus-like particle vaccines for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013; 12:155-67; PMID:23414407; http://dx.doi.org/10.1586/erv.12.145
42. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117:40-8; PMID:10381908; http://dx.doi.org/10. 1016/S0016-5085(99)70548-2
43. Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol 2003; 108:241-7; PMID:14499247; http://dx.doi.org/10. 1016/S1521-6616(03)00120-7
44. El-Kamary SS, Pasetti MF, Mendelman PM, Frey SE, Bernstein DI, Treanor JJ, Ferreira J, Chen WH, Sublett R, Richardson C, et al. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis 2010; 202:1649-58; PMID:20979455; http://dx.doi.org/10.1086/657087
45. Ramirez K, Wahid R, Richardson C, Bargatze RF, El-Kamary SS, Sztein MB, Pasetti MF. Intranasal vaccination with an adjuvanted Norwalk virus-like particle vaccine elicits antigen-specific B memory responses in human adult volunteers. Clin Immunol 2012; 144:98-108; PMID:22710446; http://dx.doi.org/10. 1016/j.clim.2012.05.006
46. Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011; 365:2178-87; PMID:22150036; http://dx.doi.org/10.1056/NEJMoa1101245
47. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67; PMID:2371542; http://dx.doi.org/10.3109/00365549009027046
48. Ruuska T, Vesikari T. A prospective study of acute diarrhoea in Finnish children from birth to 2 1/2 years of age. Acta Paediatr Scand 1991; 80:500-7; PMID:1872172; http://dx.doi.org/10.1111/j.1651-2227.1991.tb11893.x
49. Tan M, Hegde RS, Jiang X. The P domain of norovirus capsid protein forms dimer and binds to histo-blood group antigen receptors. J Virol 2004; 78:6233-42; PMID:15163716; http://dx.doi.org/10.1128/JVI.78.12.6233-6242.2004
50. Bu W, Mamedova A, Tan M, Xia M, Jiang X, Hegde RS. Structural basis for the receptor binding specificity of Norwalk virus. J Virol 2008; 82:5340-7; PMID:18385236; http://dx.doi.org/10.1128/JVI.00135-08
51. Cao S, Lou Z, Tan M, Chen Y, Liu Y, Zhang Z, Zhang XC, Jiang X, Li X, Rao Z. Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol 2007; 81:5949-57; PMID:17392366; http://dx.doi.org/10.1128/ JVI.00219-07
52. Chen Y, Tan M, Xia M, Hao N, Zhang XC, Huang P, Jiang X, Li X, Rao Z. Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog 2011; 7:e1002152; PMID:21811409; http://dx.doi.org/10.1371/journal.ppat.1002152
53. Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X. Noroviral P particle: structure, function and applications in virus-host interaction. Virology 2008; 382:115-23; PMID:18926552; http://dx.doi.org/10. 1016/j.virol.2008.08.047
54. Tan M, Jiang X. The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol 2005; 79:14017-30; PMID:16254337; http://dx.doi.org/10.1128/JVI.79.22.14017-14030.2005
55. Tan M, Fang PA, Xia M, Chachiyo T, Jiang W, Jiang X. Terminal modifications of norovirus P domain resulted in a new type of subviral particles, the small P particles. Virology 2011; 410:345-52; PMID:21185050; http://dx.doi.org/10.1016/j.virol.2010.11.017
56. Wang L, Huang P, Fang H, Xia M, Zhong W, McNeal MM, Jiang X, Tan M. Polyvalent complexes for vaccine development. Biomaterials 2013; 34:4480-92; PMID:23498893; http://dx.doi.org/10.1016/j.biomaterials.2013.02.041
57. Fang H, Tan M, Xia M, Wang L, Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One 2013; 8:e63269; PMID:23638188; http://dx.doi.org/10.1371/journal.pone.0063269
58. Dai YC, Wang YY, Zhang XF, Tan M, Xia M, Wu XB, Jiang X, Nie J. Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles. J Virol Methods 2012; 186:126-31; PMID:22867844; http://dx.doi.org/10.1016/j.jviromet.2012.07.002
59. Dai YC, Zhang XF, Tan M, Huang P, Lei W, Fang H, Zhong W, Jiang X. A dual chicken IgY against rotavirus and norovirus. Antiviral Res 2013; 97:293-300 PMID:23267830
60. Tan M, Huang P, Xia M, Fang P-A, Zhong W, McNeal M, Wei C, Jiang W, Jiang X. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011; 85:753-64; PMID:21068235; http://dx.doi.org/10.1128/ JVI.01835-10
61. Tan M, Huang P, Xia M, Fang PA, Zhong W, McNeal M, Wei C, Jiang W, Jiang X. Norovirus P particle, a novel platform for vaccine development and antibody production. J Virol 2011; 85:753-64; PMID:21068235; http://dx.doi.org/10.1128/ JVI.01835-10
62. Xia M, Tan M, Wei C, Zhong W, Wang L, McNeal M, Jiang X. A candidate dual vaccine against influenza and noroviruses. Vaccine 2011; 29:7670-7; PMID:21839795; http://dx.doi.org/10.1016/j.vaccine.2011.07.139
63. Wang L, Cao D, Wei C, Meng XJ, Jiang X, Tan M. A dual vaccine candidate against norovirus and hepatitis E virus. Vaccine 2014; 32:445-52 PMID:24291540
64. Tan M, Xia M, Huang P, Wang L, Zhong W, McNeal M, Wei C, Jiang X. Norovirus P Particle as a Platform for Antigen Presentation. Procedia in Vaccinology 2011; 4:19-26; http://dx.doi.org/10.1016/j.provac.2011.07.004
65. Wyatt RG, Greenberg HB, Dalgard DW, Allen WP, Sly DL, Thornhill TS, Chanock RM, Kapikian AZ. Experimental infection of chimpanzees with the Norwalk agent of epidemic viral gastroenteritis. J Med Virol 1978; 2:89-96; PMID:97364; http://dx.doi.org/10.1002/jmv.1890020203
66. Rockx BH, Bogers WM, Heeney JL, van Amerongen G, Koopmans MP. Experimental norovirus infections in non-human primates. J Med Virol 2005; 75:313-20; PMID:15602728; http://dx.doi.org/10.1002/jmv.20273
67. Subekti DS, Tjaniadi P, Lesmana M, McArdle J, Iskandriati D, Budiarsa IN, Walujo P, Suparto IH, Winoto I, Campbell JR, et al. Experimental infection of Macaca nemestrina with a Toronto Norwalk-like virus of epidemic viral gastroenteritis. J Med Virol 2002; 66:400-6; PMID:11793394; http://dx.doi.org/ 10.1002/jmv.2159
68. Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A 2011; 108:325-30; PMID:21173246; http://dx.doi.org/10.1073/pnas.1014577107
69. Bui T, Kocher J, Li Y, Wen K, Li G, Liu F, Yang X, LeRoith T, Tan M, Xia M, et al. Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J Gen Virol 2013; 94:2005-16; PMID:23804568; http://dx.doi.org/10.1099/vir.0.054080-0
70. Cheetham S, Souza M, McGregor R, Meulia T, Wang Q, Saif LJ. Binding patterns of human norovirus-like particles to buccal and intestinal tissues of gnotobiotic pigs in relation to A/H histo-blood group antigen expression. J Virol 2007; 81:3535-44; PMID:17215284; http://dx.doi.org/10.1128/JVI.01306-06
71. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J Virol 2006; 80:10372-81; PMID:17041218; http://dx.doi.org/10.1128/JVI.00809-06
72. Souza M, Costantini V, Azevedo MS, Saif LJ. A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model. Vaccine 2007; 25:8448-59; PMID:18022293; http://dx.doi.org/10.1016/j.vaccine.2007.09.040
73. Jung K, Wang Q, Kim Y, Scheuer K, Zhang Z, Shen Q, Chang KO, Saif LJ. The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS One 2012; 7:e41619; PMID:22911825; http://dx.doi.org/10.1371/journal.pone.0041619
74. Liu Y, Huang P, Tan M, Liu Y, Biesiada J, Meller J, Castello AA, Jiang B, Jiang X. Rotavirus VP8*: phylogeny, host range, and interaction with histoblood group antigens. J Virol 2012; 86:9899-910; PMID:22761376; http://dx.doi.org/10.1128/JVI.00979-12
75. Souza M, Azevedo MS, Jung K, Cheetham S, Saif LJ. Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J Virol 2008; 82:1777-86; PMID:18045944; http://dx.doi.org/10.1128/JVI.01347-07
76. Taube S, Kolawole AO, Höhne M, Wilkinson JE, Handley SA, Perry JW, Thackray LB, Akkina R, Wobus CE. A mouse model for human norovirus. MBio 2013; e00450-13:4; PMID:23860770; http://dx.doi.org/10.1128/mBio.00450-13
77. Dolin R, Levy AG, Wyatt RG, Thornhill TS, Gardner JD. Viral gastroenteritis induced by the Hawaii agent. Jejunal histopathology and serologic response. Am J Med 1975; 59:761-8; PMID:811119; http://dx.doi.org/10. 1016/0002-9343(75)90461-1
78. Dolin R, Blacklow NR, DuPont H, Buscho RF, Wyatt RG, Kasel JA, Hornick R, Chanock RM. Biological properties of Norwalk agent of acute infectious nonbacterial gastroenteritis. Proc Soc Exp Biol Med 1972; 140:578-83; PMID:4624851; http://dx.doi.org/10.3181/00379727-140-36508
79. Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med 1977; 297:86-9; PMID:405590; http://dx.doi.org/10.1056/NEJM197707142970204
80. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis 1990; 161:18-21; PMID:2153184; http://dx.doi.org/10.1093/infdis/161.1.18
81. Johnson PC, Hoy J, Mathewson JJ, Ericsson CD, DuPont HL. Occurrence of Norwalk virus infections among adults in Mexico. J Infect Dis 1990; 162:389-93; PMID:2165112; http://dx.doi.org/10.1093/infdis/162.2.389
82. Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, Thornhill TS, Kapikian AZ, Chanock RM. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis 1974; 129:709-14; PMID:4209723; http://dx.doi.org/10.1093/infdis/129.6.709
83. Zheng DP, Ando T, Fankhauser RL, Beard RS, Glass RI, Monroe SS. Norovirus classification and proposed strain nomenclature. Virology 2006; 346:312-23; PMID:16343580; http://dx.doi.org/10.1016/j.virol.2005.11.015
84. Kroneman A, Vega E, Vennema H, Vinjé J, White PA, Hansman G, Green K, Martella V, Katayama K, Koopmans M. Proposal for a unified norovirus nomenclature and genotyping. Arch Virol 2013; 158:2059-68; PMID:23615870; http://dx.doi.org/10.1007/s00705-013-1708-5
85. Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, Dickey M, McNeal M, Jiang X. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis 2012; 206:1386-93; PMID:22927452; http://dx.doi.org/10.1093/infdis/jis514
86. Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol 2005; 79:2900-9; PMID:15709009; http://dx.doi.org/10.1128/JVI.79.5.2900-2909. 2005
87. Lindesmith LC, Donaldson E, Leon J, Moe CL, Frelinger JA, Johnston RE, Weber DJ, Baric RS. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol 2010; 84:1800-15; PMID:20007270; http://dx.doi.org/10.1128/JVI.02179-09
88. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Ramani S, Hill H, Ferreira J, Graham DY. Determination of the 50% human infectious dose for norwalk virus. J Infect Dis 2014; 209:1016-22; PMID:24253285; http://dx.doi.org/10.1093/infdis/jit620
89. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 2008; 5:e31; PMID:18271619; http://dx.doi.org/10.1371/journal.pmed.0050031
90. Siebenga JJ, Vennema H, Renckens B, de Bruin E, van der Veer B, Siezen RJ, Koopmans M. Epochal evolution of GGII.4 norovirus capsid proteins from 1995 to 2006. J Virol 2007; 81:9932-41; PMID:17609280; http://dx.doi.org/10.1128/JVI. 00674-07
91. Debbink K, Donaldson EF, Lindesmith LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol 2012; 86:1214-26; PMID:22090110; http://dx.doi.org/10.1128/JVI.06189-11
92. Debbink K, Lindesmith LC, Donaldson EF, Baric RS. Norovirus immunity and the great escape. PLoS Pathog 2012; 8:e1002921; PMID:23093932; http://dx.doi.org/10.1371/journal.ppat.1002921
93. Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 2012; 8:e1002705; PMID:22615565; http://dx.doi.org/10.1371/journal.ppat.1002705
94. Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinjé J, Baric RS. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol 2013; 87:2803-13; PMID:23269783; http://dx.doi.org/10.1128/JVI.03106-12
95. Lindesmith LC, Debbink K, Swanstrom J, Vinjé J, Costantini V, Baric RS, Donaldson EF. Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol 2012; 86:873-83; PMID:22090098; http://dx.doi.org/10.1128/ JVI.06200-11
96. Yang Y, Xia M, Tan M, Huang P, Zhong W, Pang XL, Lee BE, Meller J, Wang T, Jiang X. Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol 2010; 84:9595-607; PMID:20592096; http://dx.doi.org/10.1128/JVI.02614-09
97. Lindesmith LC, Donaldson EF, Baric RS. Norovirus GII.4 strain antigenic variation. J Virol 2011; 85:231-42; PMID:20980508; http://dx.doi.org/10.1128/ JVI.01364-10
98. Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013; 8:e70409; PMID:23922988; http://dx.doi.org/ 10.1371/journal.pone.0070409
99. Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine 2011; 29:8126-33; PMID:21854823; http://dx.doi.org/10. 1016/j.vaccine.2011.08.026
100. Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol 2010; 17:1850-8; PMID:20962211; http://dx.doi.org/10.1128/CVI.00230-10
101. Ma Y, Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol 2011; 85:2942-52; PMID:21228240; http://dx.doi.org/10.1128/JVI.02332-10
102. Fang H, Tan M, Xia M, Wang L, Jiang X. Norovirus P particle efficiently elicits innate, humoral and cellular immunity. PLoS One 2013; 8:e63269; PMID:23638188; http://dx.doi.org/10.1371/journal.pone.0063269